Omicron variant KP.3.1.1, also known as deFLuQE, made up over half (52.7%) of COVID-19 cases between Sept. 1 and Sept. 14 ...
The coronavirus subvariant XEC is drawing more attention as a potential threat heading into late autumn and winter — ...
EMA’s human medicines committee recommends marketing approval for Pfizer & BioNTech’s Omicron KP.2-adapted Covid-19 vaccine: New York Monday, September 23, 2024, 10:00 Hrs [IS ...
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
By mid-September, the Centers for Disease Control and Prevention reported the Omicron subvariant KP.3.1.1 accounted for most COVID-19 cases. KP.3.1.1 is a member of a group of variants nicknamed ...
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...
The evidence that FFP3 masks were more protective for doctors than surgical masks is ‘weak’, the Covid inquiry has heard.
Exclusive: Lower levels of protective antibodies could leave the UK population vulnerable to a rapid spread of the XEC Covid ...